C-reactive protein and colorectal cancer mortality in U.S. adults

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 8, 2014, Pages 1609-1618

  Goyal, Abhishek ^a   Terry, Mary Beth ^a,b   Jin, Zhezhen ^a   Siegel, Abby B ^b  

^a Department of Medicine   (United States)

^b Department of Biostatistics Columbia University Mailman School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; FOLIC ACID; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; SATURATED FATTY ACID; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BLACK PERSON; BODY MASS; C REACTIVE PROTEIN BLOOD LEVEL; CALCIUM INTAKE; CANCER MORTALITY; CAUCASIAN; CAUSE OF DEATH; COLORECTAL CANCER; DIABETES MELLITUS; DOSE RESPONSE; DRUG USE; EDUCATION; ETHNICITY; FEMALE; FIBER; FOLLOW UP; FOOD INTAKE; HAZARD RATIO; HIGH RISK POPULATION; HIGH SCHOOL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCOME; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEXICAN AMERICAN; NEUTROPHIL COUNT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SMOKING; VITAMIN INTAKE; WAIST HIP RATIO; BLOOD; COLORECTAL TUMOR; COMPLICATION; EPIDEMIOLOGY; INFLAMMATION; METABOLISM; MORTALITY; NUTRITION; UNITED STATES;

ADULT; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; NUTRITION SURVEYS; UNITED STATES;

EID: 84905447878     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0577     Document Type: Article

References (79)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
3. Okada F, Kawaguchi T, Habelhah H, Kobayashi T, Tazawa H, Takeichi N, et al. Conversion of human colonic adenoma cells to adenocarcinoma cells through inflammation in nude mice. Lab Invest 2000;80:1617-28.
4. Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
5. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-16.
6. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14.
7. Flossmann E, Rothwell PMBritish Doctors Aspirin T, the UKTIAAT. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13.
8. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-66.
9. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
10. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
11. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
12. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011;106:1340-50.
13. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081-7.
14. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
15. Toriola AT, Ulrich CM. Isthereapotential use for C-reactiveprotein asa diagnostic and prognostic marker for colorectal cancer? Future Oncol 2011;7:1125-8.
16. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB, Rinaldi S, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172:407-18.
17. Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y, Brown E, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013;132:2648-58.
18. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-8.
19. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-23.
20. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-9.
21. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004;90:1707-9.
22. National Center for Health Statistics. The National Health and Nutrition Examination Survey (NHANES). [cited 2013 April 1]. Available from: http://www.cdc.gov/nchs/nhanes.htm
23. National Center for Health Statistics. Research Ethics Review Board (ERB) Approval. [cited 2013 April 1]. Available from: http://www.cdc. gov/nchs/nhanes/irba98.htm
24. National Center for Health Statistics. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 [cited 2013 April 1]. Available from: http://www.cdc. gov/nchs/data/nhanes/ nhanes3/cdrom/nchs/manuals/labman.pdf
25. Gunter EW, McQuillan G. Quality control in planning and operating the laboratory component for the Third National Health and Nutrition Examination Survey. J Nutr 1990;120 Suppl 11:1451-4.
26. National Center for Health Statistics. The Third National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File. [cited 2013 April 1]. Available from: http://www.cdc.gov/nchs/data/datalinkage/nh3-file- layout-public-2010.pdf
27. World Health Organization. International statistical classification of diseases and related health problems, 10th revision. Geneva, Switzerland: World Health Organization; 1992.
28. National Center for Health Statistics. The Third National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File, Mortality follow-up through 2006: Matching Methodology May 2009. [cited 2013 April 1]. Available from: http://www.cdc.gov/nchs/data/datalinkage/matching-methodology- nhanes3-final.pdf
29. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010;29:1037-57.
30. National Center for Health Statistics. The Third National Health and Nutrition Examination Survey (NHANES III), 1988-94. Analytic and Reporting Guidelines. [cited 2013 April 1]. Available from: http://www.cdc.gov/nchs/data/ nhanes/nhanes3/nh3gui.pdf
31. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
32. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007;121:368-76.
33. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007;86:s836-42.
34. Ko WF, Helzlsouer KJ, Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J Natl Cancer Inst 1994;86:1874-5.
35. Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White blood cell count and the risk of colon cancer. Yonsei Med J 2006;47:646-56.
36. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes 2008;32:304-14.
37. Huxley RR, Lean M, Crozier A, John JH, Neil HA, Oxford F, et al. Effect of dietary advice to increase fruit and vegetable consumption on plasma flavonol concentrations: results from a randomised controlled intervention trial. J Epidemiol Community Health 2004;58:288-9.
38. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
39. Festa A, D'Agostino R Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
40. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006;98:920-31.
41. Levin B. Inflammatory bowel disease and colon cancer. Cancer 1992;70:1313-6.
42. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
43. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-45.
44. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-9.
45. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006;23:1097-104.
46. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
47. Emerging Risk Factors C Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
48. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8.
49. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane SJ apan Public Health Center-Based Prospective Study G. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006;15:690-5.
50. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-7.
51. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
52. Chiu HM, Lin JT, Chen TH, Lee YC, Chiu YH, Liang JT, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008;103:2317-25.
53. Prizment AE, Anderson KE, Visvanathan K, Folsom AR. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2011;20:297-307.
54. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90.
55. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005;142:425-32.
56. Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M, Ozasa K, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol 2005;15 Suppl 2:S185-9.
57. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216-22.
58. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4.
59. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
60. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011;140:799-808.
61. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, et al. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 2011;20:428-37.
62. Song M, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013:108:1891-8.
63. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129-38.
64. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-53.
65. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-51.
66. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the FraminghamHeartStudy. CircCardiovascQualOutcomes 2008;1:92-7.
67. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003;108:155-60.
68. Gunter MJ, Cross AJ, Huang WY, Stanczyk FZ, Purdue M, Xue X, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Biomarkers Prev 2011;20:537-44.
69. Platz EA, Sutcliffe S, De Marzo AM, Drake CG, Rifai N, Hsing AW, et al. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Control 2010;21:847-51.
70. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
71. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
72. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin postdiagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013;49:1049-57.
73. Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal antiinflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer 2012;107:1602-7.
74. Bastiaannet E, Sampieri K, Dekkers OM, De Craen AJ, Van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012;106:1564-70.
75. Kennon S, Price CP, Mills PG, Ranjadayalan K, Cooper J, Clarke H, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266-70.
76. Monakier D, Mates M, Klutstein MW, Balkin JA, Rudensky B, Meerkin D, et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004;125:1610-5.
77. Win AK, Macinnis RJ, Hopper JL, Jenkins MA. Risk prediction models for colorectal cancer: a review. Cancer Epidemiol Biomarkers Prev 2012;21:398-410.
78. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
79. Slattery ML, Curtin K, Poole EM, Duggan DJ, Samowitz WS, Peters U, et al. Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. Int J Cancer 2011;128:2726-34.